BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jain S, Maque J, Galoosian A, Osuna-Garcia A, May FP. Optimal Strategies for Colorectal Cancer Screening. Curr Treat Options Oncol 2022. [PMID: 35316477 DOI: 10.1007/s11864-022-00962-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Ploukou S, Birtsou C, Gavana M, Tsakiridou K, Dandoulakis M, Symintiridou D, Moraiti E, Parisis A, Smyrnakis E. General Practitioners’ attitudes and beliefs on barriers to colorectal cancer screening: A qualitative study. Popul Med 2023;5:1-8. [DOI: 10.18332/popmed/161128] [Reference Citation Analysis]
2 Yang S, Zhao J, Liu Q. Occult colon cancer with liver abscess and pancreatitis as the first manifestations: A case report. Medicine (Baltimore) 2023;102:e32654. [PMID: 36701699 DOI: 10.1097/MD.0000000000032654] [Reference Citation Analysis]
3 Sun X, Fan J, Zhao W, Lu Q, Gu J, Lv L, Gao H, Ye G. Screening intention of MTs-DNA test for Colorectal Cancer screening and associated factors among hospital-based populations in southeastern China.. [DOI: 10.21203/rs.3.rs-2062691/v1] [Reference Citation Analysis]
4 Severskaya NV, Nevolskikh AA, Avdeenko VA, Hailova ZV, Ivanov SA. Fecal occult blood testing in colorectal cancer screening programs. Issled prakt med (Print) 2022;9:145-159. [DOI: 10.17709/2410-1893-2022-9-3-11] [Reference Citation Analysis]
5 Hirayama Y, Sato M, Watanabe K. Advancing the Biosynthetic and Chemical Understanding of the Carcinogenic Risk Factor Colibactin and Its Producers. Biochemistry 2022. [PMID: 35723977 DOI: 10.1021/acs.biochem.2c00229] [Reference Citation Analysis]